DarioHealth Reports Second Quarter 2026 Financial Results
Rhea-AI Summary
DarioHealth (NASDAQ: DRIO) reported second quarter 2026 revenue of $5.2 million, down from $5.4 million a year ago and $5.6 million in Q1 2026, mainly due to discontinuing certain pharmaceutical-related business as it shifts toward a B2B2C annual recurring revenue model.
Gross profit rose to $3.2 million and gross margin improved to about 62% versus 55% a year earlier, with non-GAAP B2B2C gross margin near 80% for the 10th straight quarter. Operating expenses fell 21% year-over-year to $9.7 million, improving operating loss to $6.5 million and net loss to $7.9 million. The company cited $13.1 million of contracted and late-stage ARR, more than 80% multi-condition, and highlighted new commercial wins including a top‑5 national health plan expansion, a fifth Fortune 50 client, and broader reach through Solera and Amwell channel partners.
Pro forma cash, cash equivalents and short‑term deposits totaled $36.8 million after raising $22.8 million net in a July 2026 at‑the‑market registered direct offering.
Positive
- Gross margin increased to 61.7% from 55.2% year-over-year
- Operating expenses down 21% year-over-year to $9.7 million
- Operating loss improved to $6.5M from $9.2M year-over-year
- Net loss improved to $7.9M from $13.0M year-over-year
- Contracted and late-stage ARR of $13.1M, majority multi-condition
- Pro forma cash balance of $36.8M after July financing
- Registered direct financing raised $22.8M net in July 2026
- Solera expansion adds 500,000+ new eligible lives
- New Fortune 50 client with 100,000+ eligible employees
- Top-5 health plan expansion could roughly triple revenue opportunity
Negative
- Quarterly revenue declined to $5.2M from $5.4M year-over-year
- Revenue also declined from $5.6M in first quarter 2026
- Net loss remains sizable at $7.9M for the quarter
- First-half 2026 revenue fell to $10.8M from $12.1M
- Long-term loan outstanding totals approximately $31.1M
- Registered direct equity financing implies shareholder dilution
News Explained
The July financing was completed through the sale of additional common stock, so it increases the total share count and reduces existing holders’ percentage ownership absent offsetting changes; the release does not quantify the resulting dilution.
Sources and calculations
- DarioHealth Reports Second Quarter 2026 Financial Results (2026-08-11)
- Dario Announces Pricing of a $23.5 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules (2026-07-22)
- Dilution (2026-07-17)
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 13 | 1Q26 earnings | Negative | -6.7% | Revenue declined year-over-year despite lower expenses and an improved operating loss. |
| Mar 19 | 4Q25 earnings | Negative | -7.7% | Quarterly and annual revenue declined following a legacy client nonrenewal. |
| Nov 13 | 3Q25 earnings | Negative | -15.6% | Revenue declined year-over-year despite margin expansion and increased ARR-client additions. |
| Aug 12 | 2Q25 earnings | Negative | -14.8% | Revenue declined despite operating improvements, new clients, and higher gross margin. |
| May 14 | 1Q25 earnings | Negative | -8.5% | Sequential revenue declined despite improved margins, expenses, operating loss, and client additions. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
All five tag-specific earnings events had negative 24-hour reactions, with an average move of -10.67%.
Key Terms
non-gaap financial
b2b2c financial
annual recurring revenue financial
at-the-market financial
registered direct financing financial
ieepa regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Second quarter 2026 revenue was
$5.2 million - Gross margin increased to
62% , compared to57% in the first quarter of 2026 and55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately80% for the 10th consecutive quarter - Operating loss decreased by
30% year-over-year and11% quarter-over-quarter - Operating expenses declined by
21% year-over-year and8% quarter-over-quarter - Multi-condition strategy compounding: more than
80% of the$13.1 million - Commercial momentum with three significant wins in recent weeks, led by a top-5 national health plan expansion with the potential to approximately triple Dario's potential revenue opportunity — its third such expansion — plus a 5th Fortune 50 client and a new health insurer via the Amwell channel
- Expanded into provider-backed clinical care delivery, accessing a larger portion of the healthcare value chain and increasing the potential revenue opportunity per client
- Pro forma cash of
$36.8 million $22.8 million - Conference call today, August 11, 2026 at 8:30 am ET
"We believe that Dario has reached an important stage where the investments made in our technology, product, and distribution infrastructure are compounding positive momentum," said Erez Raphael, Chief Executive Officer of Dario. "Over the past decade, we have built a comprehensive multi-condition platform supported by robust clinical evidence, enterprise distribution generating ARR and, more recently, AI-powered capabilities that have the potential to increase the recurring revenue we generate from customers we have already won. Our strategy is translating into execution as new customers are increasingly adopting our multi-condition solutions and existing customers expand into additional conditions. Today, we believe provider-backed care is the natural extension of our platform, positioning us to capture a larger share of the healthcare value chain. We believe we have built an end-to-end chronic care platform that is unique in the market and positions us to accelerate revenue growth by the end of 2026 and into 2027."
Commercial Highlights:
Dario has served more than a dozen health plans over the last 4 quarters, including 3 national carriers, across more than 6 chronic condition solutions, with 5 Fortune 50 clients and approximately
Added New Enterprise Accounts Through Channel Partners
- Signed new Fortune 50 client representing more than 100,000 eligible employees, Dario's 5th Fortune 50 client; the Company expects ARR contribution to begin at the end of 2026 and ramp into 2027
- Signed a major health insurer with a stronghold in
Arizona , representing hundreds of thousands of lives, through the Amwell channel partnership
Expanded Within Existing Customers
- Top 5 national health plan extended its behavioral health agreement and added Dario's hypertension solution, the third such plan to expand number of conditions; the expansion has the potential to approximately triple Dario's potential revenue opportunity under this relationship, with contribution expected in 2026 and higher impact in 2027 and onward, demonstrating Dario's land-and-expand strategy
- Channel partner Solera expanded its contract to add Dario's hypertension program across its existing member base, addressing an additional 500,000+ new eligible lives, approximately doubling Dario's addressable eligible population through Solera
Added Product Extensions
- The Company expects the new programs to begin revenue contribution in the fourth quarter of 2026
- Dario Women supports members navigating perimenopause and menopause, life stages frequently associated with weight changes, sleep disruption, metabolic changes and increased cardiometabolic risk
- Dario Sleep addresses obstructive sleep apnea ("OSA"), a significant contributor to cardiometabolic disease and rising healthcare costs
Extended Into Provider-Backed Care
- Expanded into provider-backed care through Beluga Health's care delivery infrastructure, adding 50-state embedded clinical delivery, expanding Dario's platform beyond digital engagement to include provider-led care capabilities
- Launched the first provider-backed offering, Dario's Integrated GLP-1 Program, combining the digital platform with GLP-1 medical evaluation, prescribing and oversight
DarioIQ: The Engine Underneath
- More than 13 billion proprietary longitudinal data points from FDA-cleared connected devices power a vertically integrated device-to-data-to-AI stack, and support delivery of integrated multi-condition care
- Broad deployment of DarioIQ, which the Company believes could contribute an increase of 10
-15% in B2B2C ARR from existing customers through higher engagement, retention and clinical outcomes - Applied within Dario's own operations, AI has helped expand operational capability while holding the cost base, contributing to the reduction in operating expenses and operating loss this quarter
Lara Dodo, Dario's Chief Operating Officer, commented, "Commercial execution remained strong during the second quarter of 2026 as we continued advancing enterprise customer implementations, expanding relationships with channel partners and broadening adoption of our integrated multi-condition platform. We swiftly advanced our provider-backed care strategy and implementation, expanding our ability to increase long-term customer value."
Second Quarter 2026 Financial Highlights:
- Revenue was
$5.2 million $5.6 million $5.4 million - Gross profit increased to
$3.2 million 8% year-over-year and substantially consistent quarter-over-quarter - Gross margin increased to
62% , compared with57% in the first quarter of 2026 and55% in the second quarter of 2025; Non-GAAP B2B2C gross margins remain at approximately80% for the 10th consecutive quarter - Operating expenses declined to
$9.7 million 8% quarter-over-quarter and21% year-over-year, while operating loss improved11% quarter-over-quarter and30% year-over-year - Balance sheet strengthened with
$36.8 million $14.0 million $22.8 million
"Our second quarter results reflect continued progress in improving the efficiency of our business, with improvements in gross margin, operating expenses and net loss, year-over-year," stated Chen Franco Yehuda, Dario's Chief Financial Officer. "Following quarter end, we strengthened our balance sheet through a successful
Second Quarter 2026 Financial Results
Revenue was
Gross profit was
Operating expenses declined to
Net loss was
Non-GAAP operating loss (excluding stock-based compensation, acquisition related expenses, depreciation and amortization expenses) for the three months ended June 30, 2026 was
A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Six Months Ended June 30, 2026
Revenue for the first six months of 2026 was
Gross profit was
Operating expenses decreased to
Net loss improved to
Non-GAAP operating loss (excluding stock-based compensation, acquisition related expenses, depreciation and amortization expenses) for the six months ended June 30, 2026 was
A reconciliation of GAAP to non-GAAP measures has been provided in the financial statement tables included in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."
Conference Call Details
Date: Tuesday, August 11th, 2026, 8:30 a.m. Eastern Time
Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)
Call me™: https://emportal.ink/4vKeztO
Participants can use the dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. This link will be made active 15 minutes prior to the scheduled start time.
Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1767650&tp_key=4cfb9bb10d
Participants are asked to dial in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately three hours after completion of the conference call through Tuesday, August 25th, 2026. To listen to the replay, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use replay passcode 1188083.
About DarioHealth Corp. (Nasdaq: DRIO)
DarioHealth (Nasdaq:DRIO) is an AI-powered healthcare technology company helping health plans, health systems and employers improve health outcomes while lowering the cost of care. The Company's integrated platform combines connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs.
Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario's AI platform personalizes care at the individual member level by analyzing biometric, clinical and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses its expected revenue growth and commercial momentum, the expected timing and contribution of ARR, the anticipated implementation and expansion of customer relationships, including the top-5 national health plan expansion and new Fortune 50 client, the potential revenue opportunity associated with customer expansions, the expected launch and revenue contribution of new product offerings, the anticipated benefits of its provider-backed care strategy and DarioIQ™ platform, the expected impact of AI on customer engagement, retention, clinical outcomes and operating efficiency, the Company's ability to accelerate revenue growth by the end of 2026 and into 2027, and the Company's future financial performance and business strategy. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Non-GAAP Financial Measures
This release includes financial measures that are not prepared in accordance with U.S. GAAP. Management uses these non-GAAP measures internally to evaluate ongoing operating performance and believes they provide investors with additional insight when used as a supplement to GAAP measures. Non-GAAP measures should not be considered in isolation from, or as a substitute for, GAAP measures. A reconciliation of GAAP to non-GAAP measures is provided in the financial tables included in this release.
Operating expenses (non-GAAP). Our presentation of non-GAAP operating expenses excludes stock-based compensation expenses, amortization of acquisition-related expenses and depreciation of fixed assets. Due to varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's non-cash operating expenses, we believe that providing non-GAAP financial measures that exclude non-cash expenses provides us with an important tool for financial and operational decision making and for evaluating our own core business operating results over different periods of time.
Net loss (non-GAAP). Our presentation of adjusted net loss excludes the effect of certain items that are non-GAAP financial measures. Adjusted net loss represents net loss determined under GAAP without regard to stock-based compensation expenses, depreciation and impairment expense, amortization of acquired technology and brand, financial (income) expenses, net, income tax, and acquisition costs. We believe these measures provide useful information to management and investors for analysis of our operating results.
DarioHealth Corporate Contacts
Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310
Zoe Harrison
VP, Accounting and Corporate Development
irteam@dariohealth.com
CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (UNAUDITED) | ||||||
June 30, | December 31, | |||||
2026 | 2025 | |||||
ASSETS | ||||||
CURRENT ASSETS: | ||||||
Cash and cash equivalents | $ | 6,634 | $ | 21,803 | ||
Short-term bank deposits | 7,327 | 4,214 | ||||
Short-term restricted bank deposits | 293 | 229 | ||||
Trade receivables, net | 1,549 | 2,144 | ||||
Inventories | 3,719 | 4,316 | ||||
Other accounts receivable and prepaid expenses | 2,604 | 2,361 | ||||
Total current assets | 22,126 | 35,067 | ||||
NON-CURRENT ASSETS: | ||||||
Deposits | 119 | 80 | ||||
Operating lease right of use assets | 1,029 | 717 | ||||
Long-term assets | 386 | 304 | ||||
Property and equipment, net | 503 | 549 | ||||
Intangible assets, net | 15,000 | 15,931 | ||||
Goodwill | 57,427 | 57,427 | ||||
Total non-current assets | 74,464 | 75,008 | ||||
Total assets | $ | 96,590 | $ | 110,075 | ||
The accompanying notes are an integral part of the unaudited condensed consolidated interim financial statements. | ||||||
CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (UNAUDITED) | ||||||
June 30, | December 31, | |||||
2026 | 2025 | |||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
CURRENT LIABILITIES: | ||||||
Trade payables | $ | 3,173 | $ | 2,928 | ||
Deferred revenues | 521 | 714 | ||||
Operating lease liabilities | 572 | 430 | ||||
Other accounts payable and accrued expenses | 5,312 | 5,251 | ||||
Total current liabilities | 9,578 | 9,323 | ||||
NON-CURRENT LIABILITIES | ||||||
Operating lease liabilities | 777 | 571 | ||||
Long-term loan | 31,064 | 30,747 | ||||
Warrant liability | 15 | 1,466 | ||||
Other long-term liabilities | 68 | 46 | ||||
Total non-current liabilities | 31,924 | 32,830 | ||||
STOCKHOLDERS' EQUITY ** | ||||||
Common stock of | 4 | 4 | ||||
Additional paid-in capital | 523,335 | 519,996 | ||||
Accumulated deficit | (468,251) | (452,078) | ||||
Total stockholders' equity | 55,088 | 67,922 | ||||
Total liabilities and stockholders' equity | $ | 96,590 | $ | 110,075 | ||
The accompanying notes are an integral part of the unaudited condensed consolidated interim financial statements. | ||||||
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) | ||||||||||||
Three months ended | Six months ended | |||||||||||
June 30, | June 30, | |||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||
Revenues: | ||||||||||||
Services | $ | 2,585 | $ | 3,661 | $ | 5,410 | $ | 8,536 | ||||
Consumer hardware | 2,592 | 1,708 | 5,350 | 3,585 | ||||||||
Total revenues | 5,177 | 5,369 | 10,760 | 12,121 | ||||||||
Cost of revenues: | ||||||||||||
Services | 440 | 821 | 1,002 | 1,686 | ||||||||
Consumer hardware | 1,367 | 1,151 | 3,010 | 2,281 | ||||||||
Amortization of acquired intangible assets | 178 | 433 | 354 | 1,308 | ||||||||
Total cost of revenues | 1,985 | 2,405 | 4,366 | 5,275 | ||||||||
Gross profit | 3,192 | 2,964 | 6,394 | 6,846 | ||||||||
Operating expenses: | ||||||||||||
Research and development | $ | 2,100 | $ | 3,721 | $ | 4,485 | $ | 7,829 | ||||
Sales and marketing | 4,971 | 5,231 | 9,870 | 11,104 | ||||||||
General and administrative | 2,600 | 3,212 | 5,826 | 6,522 | ||||||||
Total operating expenses | 9,671 | 12,164 | 20,181 | 25,455 | ||||||||
Operating loss | 6,479 | 9,200 | 13,787 | 18,609 | ||||||||
Interest expenses | 1,123 | — | 2,273 | — | ||||||||
Other financial expenses (income), net | (6) | 3,790 | (271) | 3,586 | ||||||||
Total financial expenses, net | 1,117 | 3,790 | 2,002 | 3,586 | ||||||||
Loss before taxes | 7,596 | 12,990 | 15,789 | 22,195 | ||||||||
Income tax | 328 | — | 384 | 22 | ||||||||
Net loss | $ | 7,924 | $ | 12,990 | $ | 16,173 | $ | 22,217 | ||||
Deemed dividend | $ | — | $ | 5,572 | $ | — | $ | 10,411 | ||||
Net loss attributable to common shareholders | $ | 7,924 | $ | 18,562 | $ | 16,173 | $ | 32,628 | ||||
Net loss per share: | ||||||||||||
Basic and diluted loss per share of common stock | $ | 0.85 | $ | 3.54 | $ | 1.75 | $ | 6.50 | ||||
Weighted average number of common stock | 9,343,618 | 2,481,548 | 9,238,133 | 2,425,039 | ||||||||
The accompanying notes are an integral part of the unaudited condensed consolidated interim financial statements. | ||||||||||||
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (UNAUDITED) | ||||||
Six months ended | ||||||
June 30, | ||||||
2026 | 2025 | |||||
Cash flows from operating activities: | ||||||
Net loss | $ | (16,173) | $ | (22,217) | ||
Adjustments required to reconcile net loss to net cash used in operating activities: | ||||||
Stock-based compensation | 2,073 | 4,377 | ||||
Change in operating lease right of use assets | 237 | 204 | ||||
Amortization of acquired intangible assets | 931 | 1,884 | ||||
Depreciation and impairment | 108 | 174 | ||||
Change in fair value of warrant liability | (185) | (825) | ||||
Accrued interest on short term bank deposits | (63) | — | ||||
Non-cash financial expenses | 265 | 2,665 | ||||
Changes in operating assets and liabilities: | ||||||
Decrease in trade receivables, net | 595 | 2,248 | ||||
Increase in other accounts receivable, prepaid expense and long-term assets | (364) | (484) | ||||
Decrease in inventories | 597 | 143 | ||||
Increase in trade payables | 232 | 334 | ||||
Increase (decrease) in other accounts payable and accrued expenses | 83 | (858) | ||||
Decrease in deferred revenues | (193) | (856) | ||||
Decrease in operating lease liabilities | (201) | (147) | ||||
Other | (50) | 654 | ||||
Net cash used in operating activities | (12,108) | (12,704) | ||||
Cash flows from investing activities: | ||||||
Investment in short term bank deposit | (9,250) | — | ||||
Proceeds from maturity of short-term bank deposit | 6,200 | — | ||||
Purchase of property and equipment | (69) | (75) | ||||
Disposals of property and equipment | 6 | — | ||||
Net cash used in investing activities | (3,113) | (75) | ||||
Cash flows from financing activities: | ||||||
Proceeds from ATM Equity Offerings | 104 | — | ||||
Issuance costs related to ATM Equity Offerings | (104) | — | ||||
Proceeds from issuance of common stock and preferred stock, net of issuance costs | — | 6,754 | ||||
Proceeds from borrowings on credit agreement | — | 31,700 | ||||
Repayment of long-term loan | — | (31,515) | ||||
Net cash provided by financing activities | — | 6,939 | ||||
Decrease in cash, cash equivalents and restricted cash and cash equivalents | (15,221) | (5,840) | ||||
Effect of exchange rate differences on cash, cash equivalents and restricted cash and cash | 52 | 30 | ||||
Cash, cash equivalents and restricted cash and cash equivalents at beginning of period | 21,803 | 27,764 | ||||
Cash, cash equivalents and restricted cash and cash equivalents at end of period | $ | 6,634 | $ | 21,954 | ||
Supplemental disclosure of cash flow information: | ||||||
Cash paid during the period for interest on long-term loan | $ | 1,930 | $ | 1,250 | ||
Non-cash activities: | ||||||
Exercise of pre-funded warrants to common stock | $ | 1,266 | $ | 1,750 | ||
Right-of-use assets obtained in exchange for lease liabilities | $ | 549 | $ | — | ||
Purchase of property and equipment on credit | $ | 13 | $ | — | ||
The accompanying notes are an integral part of the unaudited condensed consolidated interim financial statements. | ||||||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
Three months ended June 30, 2026 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 1,985 | (2) | (180) | 1,803 | |||
Gross Profit | 3,192 | 2 | 180 | 3,374 | ||||
Research and development | 2,100 | 134 | (24) | 2,210 | ||||
Sales and Marketing | 4,971 | (308) | (299) | 4,364 | ||||
General and Administrative | 2,600 | (456) | (12) | 2,132 | ||||
Total Operating Expenses | 9,671 | (630) | (355) | 8,706 | ||||
Operating Loss | $ | (6,479) | 632 | 515 | (5,332) | |||
Financing expenses | 1,117 | - | - | 1,117 | ||||
Income Tax | 328 | - | - | 328 | ||||
Net Loss | $ | (7,924) | 632 | 515 | (6,777) | |||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
Three months ended June 30, 2025 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 2,405 | (6) | (447) | 1,952 | |||
Gross Profit | 2,964 | 6 | 447 | 3,417 | ||||
Research and development | 3,721 | (441) | (34) | 3,246 | ||||
Sales and Marketing | 5,231 | (583) | (307) | 4,341 | ||||
General and Administrative | 3,212 | (1,005) | (14) | 2,193 | ||||
Total Operating Expenses | 12,164 | (2,029) | (355) | 9,780 | ||||
Operating Loss | $ | (9,200) | 2,035 | 802 | (6,363) | |||
Financing expenses | 3,790 | - | - | 3,790 | ||||
Net Loss | $ | (12,990) | 2,035 | 802 | (10,153) | |||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
Six months ended June 30, 2026 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 4,366 | (7) | (360) | 3,999 | |||
Gross Profit | 6,394 | 7 | 360 | 6,761 | ||||
Research and development | 4,485 | 42 | (56) | 4,471 | ||||
Sales and Marketing | 9,870 | (441) | (598) | 8,831 | ||||
General and Administrative | 5,826 | (1,667) | (25) | 4,134 | ||||
Total Operating Expenses | 20,181 | (2,066) | (679) | 17,436 | ||||
Operating Loss | $ | (13,787) | 2,073 | 1,039 | (10,675) | |||
Financing expenses | 2,002 | - | - | 2,002 | ||||
Income Tax | 384 | - | - | 384 | ||||
Net Loss | $ | (16,173) | 2,073 | 1,039 | (13,061) | |||
Reconciliation of Operating Loss, Net Loss and Operating Expenses to Adjusted | ||||||||
Operating Loss, Net Loss and Operating Expenses (Non-GAAP) | ||||||||
Six months ended June 30, 2025 | ||||||||
GAAP | Stock-Based | Amortization of | Non-GAAP | |||||
Cost of Revenues | $ | 5,275 | (16) | (1,337) | 3,922 | |||
Gross Profit | 6,846 | 16 | 1,337 | 8,199 | ||||
Research and development | 7,829 | (967) | (74) | 6,788 | ||||
Sales and Marketing | 11,104 | (1,398) | (618) | 9,088 | ||||
General and Administrative | 6,522 | (1,996) | (29) | 4,497 | ||||
Total Operating Expenses | 25,455 | (4,361) | (721) | 20,373 | ||||
Operating Loss | $ | (18,609) | 4,377 | 2,058 | (12,174) | |||
Financing expenses | 3,586 | - | - | 3,586 | ||||
Income Tax | 22 | - | - | 22 | ||||
Net Loss | $ | (22,217) | 4,377 | 2,058 | (15,782) | |||
Logo - https://mma.prnewswire.com/media/2866807/6031067/Dario_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/dariohealth-reports-second-quarter-2026-financial-results-302848170.html
SOURCE DarioHealth Corp.